Apricus forms sexual dysfunction committees

Details: Category: News; Published on Sunday, 27 March 2011 19:05; Written by Lara Landis; Hits: 5229

Femprox and Libigel are competing to become the first drugs on the market for Female Sexual Arousal Disorders. Like Biosante's Libigel, the drug is targeted mostly at post menopausal women who normally experience a decrease of libido after the change of life.

The Food and Drug Administration did not give flibanserin approval for its attempt to market a female viagra earlier this year. Libigel and Femprox attempt to correct the declining libido that occurs with age. Neither product seems to target the Asexual community. Hypocative Sexual Desire Disorder in men will remain, although Hypoactive Sexual Desire Disorder in women will be renamed Sexual Arousal/Disinterest Disorder in women, according to dsm5.org.

To further its goals with product development, Apricus formed a committee to investigage male and female sexual dysfunction. Irwin Goldstein, M.D., Jed Kaminetsky, M.D. and Ajay Nehra,

M.D. will lead this committee. The drug has undergone one key Phase III trial in the United States and one Phase III trial in China, according to the Globe News Wire. Femprox achieved a 44% percent rate over a placebo.

Although HSDD remains controversial, Femprox acts more like the long-sought after 'female Viagra'. Femprox, a combination of alprostadil and DDAIP relaxes the Vulvar and Clitoral muscles and increases blood flow to the area. Unlike the Biosante testosterone gel product, Fempox is not designed to increase the patient's libido and does not contain any testosterone.